Molecular biomarkers for urothelial carcinoma of the bladder: Challenges in clinical use

Nature Clinical Practice Urology

Volumn 5, Issue 12, 2008, Pages 676-685

  Bolenz, Christian ^a,b   Lotan, Yair ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CASPASE 3; CISPLATIN; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; GEMCITABINE; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; SURVIVIN; TRASTUZUMAB; TUMOR MARKER;

BLADDER CARCINOMA; CANCER CLASSIFICATION; CANCER GENETICS; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYSTECTOMY; GENE MUTATION; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UROTHELIAL CARCINOMA OF THE BLADDER;

CLINICAL TRIALS AS TOPIC; HUMANS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 57449088597     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1259     Document Type: Review

References (84)

1. Jemal A et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96
2. Sylvester RJ et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 49: 466-475
3. Shariat SF et al. (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol 176: 2414-2422
4. Stein JP et al. (2001) Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19: 666-675
5. Bochner BH et al. (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24: 3967-3972
6. Karakiewicz PI et al. (2006) Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176: 1354-1361
7. Shariat SF et al. (2006) Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12: 6663-6676
8. Freiha F et al. (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155 495-499
9. Lehmann J et al. (2006) Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 97: 42-47
10. Skinner DG et al. (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 145: 459-464
11. Stöckle M et al. (1992) Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148: 302-306
12. Ilyin SE et al. (2004) Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol 22 411-416
13. Egawa S and Kuruma H (2006) Search for biomarkers of aggressiveness in bladder cancer. Eur Urol 50: 20-22
14. Karam JA et al. (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8: 128-136
15. Shariat SF et al. (2007) Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177: 481-487
16. Shariat SF et al. (2008) Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112: 315-325
17. Shariat SF et al. (2004) p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22: 1014-1024
18. Shariat SF et al. (2007) Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 20: 445-459
19. Wu XR (2005) Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5: 713-725
20. Kim WJ and Bae SC (2008) Molecular biomarkers in urothelial bladder cancer. Cancer Sci 99: 646-652
21. Schulz WA (2006) Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119: 1513-1518
22. Chatterjee et al. (2004) Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22: 1007-1013
23. Cote RJ et al. (1997) p53 and treatment of bladder cancer. Nature 385:123-125
24. Esrig D et al. (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143: 1389-1397
25. Grossman HB et al. (1998) p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4: 829-834
26. Malats N et al. (2005) P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6: 678-686
27. George B et al. (2007) p53 gene and protein status: The role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 25: 5352-5358
28. Mitra AP et al. (2006) Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J Clin Oncol 24: 5552-5564
29. Benedict WF et al. (1999) Level of retinoblastoma protein expression correlates with p1 6 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18: 1197-1203
30. Cordon-Cardo C et al. (1992) Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251-1256
31. Cote RJ et al. (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58: 1090-1094
32. Esrig D et al. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264
33. Sarkis AS et al. (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85: 53-59
34. Stein JP et al. (1998) Effect of p21 WAF1/C1P1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90: 1072-1079
35. Margulis V et al. (2006) Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 12: 7369-7373
36. Billerey C et al. (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158: 1955-1959
37. Lipponen P and Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69: 1120-1125
38. Mhawech-Fauceglia P et al. (2007) Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: A high throughput tissue microarray analysis. BJU Int 100: 1182-1187
39. Yamana K et al. (2005) Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: Decreased expression of Fas is associated with disease progression. Br J Cancer 93: 544-551
40. Akhtar M et al. (2006) Survivin: Role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol 13: 122-126
41. Shariat SF et al. (2007) Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109: 1106-1113
42. Crew JP et al. (1997) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57: 5281-5285
43. Elkin M et al. (1999) Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 59: 4111-4118
44. Papathoma AS et al. (2000) Prognostic significance of matrix metal loprotei nases 2 and 9 in bladder cancer. Anticancer Res 20: 2009-2013
45. Bochner BH et al. (1995) Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87: 1603-1612
46. Fernandez MI et al. (2008) Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. Eur Urol 53: 571-578
47. Harrell FE et al. (1982) Evaluating the yield of medical tests. JAMA 247: 2543-2546
48. Harrell FE et al. (1996) Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387
49. Bensalah K et al. (2007) Challenges of cancer biomarker profiling. Eur Urol 52: 1601-1609
50. Lamy A et al. (2006) Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 176: 2686-2689
51. Yurakh AO et al. (2006) Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 50: 506-515
52. Shariat SF et al. (2000) Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 56: 735-740
53. Fleshner N et al. (2000) p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 164 1177-1182
54. Frank I et al. (2004) Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 101: 1803-1808
55. Dalbagni G et al. (2007) Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 99: 281-285
56. Lopez-Knowles E et al. (2006) The p53 pathway and outcome among patients with T1 G3 bladder tumors. Clin Cancer Res 12: 6029-6036
57. Moonen PM et al. (2007) Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 177 80-83
58. Hernandez S et al. (2005) FGFR3 and Tp53 mutations in T1 G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 11: 5444-5450
59. Lerner SP (2005) Bladder cancer clinical trials. Urol Oncol 23 275-279
60. p53 Targeted-Therapy Trial in Bladder Cancer [https://www.uscnorris.com/ p53]
61. Lopez-Beltran A et al. (2006) Cyclin D3 expression in primary Ta/ T1 bladder cancer. J Pathol 209: 106-113
62. Shariat SF et al. (2007) Association of cyclin D1 and El expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 25: 468-475
63. Grossfeld GD et al. (1997) Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89: 219-227
64. Cordon-Cardo C et al. (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57: 1217-1221
65. Shariat SF et al. (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61: 1140-1145
66. Shariat SF et al. (2006) Correlation of cyclin D1 and El expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 37: 1568-1576
67. Shariat SF et al. (2005) Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173: 1518-1525
68. Catto JW et al. (2003) Artificial intelligence in predicting bladder cancer outcome: A comparison of neuro-fuzzy modeling and artificial neural networks. Clin Cancer Res 9: 4172-4177
69. Qureshi KN et al. (2000) Neural network analysis of clinicopathological and molecular markers in bladder cancer. J Urol 163: 630-633
70. Shariat SF et al. (2008) Combination of cell cycle regulating bio-markers improves prognosis in patients with organ confined urothelial cancer at radical cystectomy [abstract #1690]. J Urol 179 (4 Suppl): 578
71. Grossman HB et al. (2006) Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A Southwest Oncology Group Study. Oncol Rep 16: 807-810
72. Therasse P et al. (2006) Clinical trials design and treatment tailoring: General principles applied to breast cancer research. Crit Rev Oncol Hematol 59: 98-105
73. Bellmunt J et al. (2008) Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol [doi:10.1016/ j.critrevonc.2008.06.002]
74. Als AB et al. (2007) Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13: 4407-4414
75. Sternberg CN et al. (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19: 2638-2646
76. Escudier B et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134
77. Motzer RJ et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
78. Mellon K et al. (1995) Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153: 919-925
79. Kassouf W et al. (2006) Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 176: 787-792
80. Philips GK et al. (2008) A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: Results of the Cancer and Leukaemia Group B 90102. BJU Int 101: 20-25
81. Gandour-Edwards R et al. (2002) Does H ER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95: 1009-1015
82. Hussain MH et al. (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/ neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25: 2218-2224
83. Sonpavde G et al. (2008) Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol [doi:10.1016/j.urolonc.2008.03.017]
84. Bradley DA et al. (2007) Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design. Clin Genitourin Cancer 5: 460-463